Pinealon research

The Pinealon evidence base cited here is 3 sources — 1 preclinical, 1 review. Critically, that evidence is almost entirely preclinical (animal and in-vitro) — no human clinical trials are cited, so efficacy and safety in people remain unproven. Regulatory status: Not FDA-approved.

• Pinealon (Glu-Asp-Arg, 'EDR') is a synthetic tripeptide 'bioregulator' from the Russian Khavinson short-peptide tradition, marketed for neuroprotection and cognitive enhancement.
• Its signature mechanistic claim — that the peptide directly binds DNA to modulate gene expression — is a hallmark of this family and is NOT well established in mainstream literature. Read it skeptically.
• The evidence is predominantly Russian-authored animal/cell work; a frequently cited '72-patient TBI study' isn't among the verifiable preclinical references and needs independent confirmation.

Pinealon is one of the 'short peptide bioregulators' developed in Russia under Vladimir Khavinson — the same tradition as Epitalon, Cortexin, and Thymalin. It's marketed for brain protection and cognition, with claims of direct gene-expression effects.

Two honest caveats frame everything below: this class's defining mechanism (peptides directly regulating DNA) is not broadly accepted outside the Russian literature, and the human evidence is thin. It is not FDA-approved; everything here is research context, not medical guidance.

Pinealon is a synthetic tripeptide — Glu-Asp-Arg (EDR), ~418 Da, just three amino acids — making it one of the smallest peptides in research use. Like the rest of the Khavinson bioregulator family, it is proposed to act at very low concentrations.

Its small size is cited as the basis for cell penetration and (in the family's framing) for reaching the cell nucleus to influence gene expression — a claim that should be treated as hypothesis, not established fact.

The proposed mechanism is direct interaction with DNA to modulate the expression of genes involved in neuroprotection and antioxidant defense. In preclinical models, EDR has been associated with preserved dendritic spines (via MAPK/ERK signaling), modulation of hippocampal NMDA-receptor expression, and reduced oxidative stress. It's important to be clear that the 'peptide binds DNA to switch genes on/off' framing central to this family is not well supported in mainstream molecular biology — the downstream effects observed in animals may operate through other pathways.

• Antioxidant modulation (2019, cell/animal): reduced reactive oxygen species.

These are animal and cell results from largely Russian-authored work. The human '72-patient TBI' claim cited on vendor pages is not among the verifiable references — confirm it independently before relying on it.

Pinealon is not FDA-approved and is sold as a research chemical for laboratory use only, not intended for human consumption. It has a history of use in Russia within the bioregulator tradition.

On the Huberman Lab podcast, Dr. Huberman and Dr. Abud Bakri made one useful factual correction: despite the name, pinealon (the tripeptide Glu-Asp-Arg, nicknamed 'EDR') is NOT derived from the pineal gland — it comes from a brain-cortex extract. (Epitalon is the pineal one.)

A single person's tracked experience plus expert commentary — a hypothesis to test, not evidence of a reliable REM effect.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.